BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DiaSys Corporation (DYX) Announces $615,000 Five Year Contract Renewal Minimum Order In Australia And New Zealand


12/18/2006 2:00:02 PM

WATERBURY, Conn., Dec. 18 /PRNewswire-FirstCall/ -- DiaSys Corporation a global healthcare products company, announced today that it has signed a five year contract renewal distribution agreement with Laboratory Diagnostics in Australia for territories covering Australia, New Zealand, Papua New Guinea and the Solomon Islands. The agreement guarantees minimum purchase orders of $615,000 for the Company's parasitology disposable products over the five-year period. Laboratory Diagnostics also represents, Binax and Diesse Diagnostics.

"We are pleased to continue our relationship with Laboratory Diagnostics, as they successfully introduced Parasep into the Australian market three years ago. Our new solvent free fecal concentration device, Parasep SF will be introduced into these territories in the first half of 2007," said Gregory Witchel, Chief Executive Officer.

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and through distributors. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. DiaSys's web address is http://www.DiaSys.com

Laboratory Diagnostics is a Company dedicated to sourcing and providing innovative niche quality products and solutions from a number of internationally recognized manufacturers. These products are provided to the diagnostic pathology laboratories, Veterinary pathology laboratories and research organizations in Australia, New Zealand and the South Pacific. Laboratory Diagnostic's web address is http://www.labdiagnostics.com.au

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.

DiaSys Corporation

CONTACT: Gregory Witchel, Chief Executive Officer of DiaSys Corporation,+1-203-755-5083



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES